4.8 Article

NRBP1-Containing CRL2/CRL4A Regulates Amyloid β Production by Targeting BRI2 and BRI3 for Degradation

期刊

CELL REPORTS
卷 30, 期 10, 页码 3478-+

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2020.02.059

关键词

-

资金

  1. JSPS KAKENHI [24590279, 15K08177, 18K06855, 24590357, 15K08279, 18K06959]
  2. Life Science Foundation of Japan
  3. Mitsui Sumitomo Insurance Welfare Foundation of Japan
  4. Stowers Institute for Medical Research, United States
  5. Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED, Japan [JP18am0101107]
  6. Kochi University Hospital Director's Discretionary Expense Research Grant
  7. Grants-in-Aid for Scientific Research [18K06855, 15K08279, 15K08177, 24590279, 18K06959, 24590357] Funding Source: KAKEN

向作者/读者索取更多资源

Alzheimer's disease (AD) is a progressive neurode-generative disease caused by accumulations of A beta peptides. Production and fibrillation of A beta are downregulated by BRI2 and BRI3, which are physiological inhibitors of amyloid precursor protein (APP) processing and A beta oligomerization. Here, we identify nuclear receptor binding protein 1 (NRBP1) as a substrate receptor of a Cullin-RING ubiquitin ligase (CRL) that targets BRI2 and BRI3 for degradation. Moreover, we demonstrate that (1) dimerized NRBP1 assembles into a functional Cul2- and Cul4A-containing heterodimeric CRL through its BC-box and an overlapping cryptic H-box, (2) both Cul2 and Cul4A contribute to NRBP1 CRL function, and (3) formation of the NRBP1 heterodimeric CRL is strongly enhanced by chaperone-like function of TSC22D3 and TSC22D4. NRBP1 knockdown in neuronal cells results in an increase in the abundance of BRI2 and BRI3 and significantly reduces A beta production. Thus, disrupting interactions between NRBP1 and its substrates BRI2 and BRI3 may provide a useful therapeutic strategy for AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据